Prostate cancer trials in South Korea

In South Korea 62 Also abroad 1481

62 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Deagu, Goyang-si, Hwasun-gun, Junggu, Seongnam, Seoul
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
Seoul
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Seoul, Songpagu
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Where
Seoul
Age
18 years to 100 years
People
42 worldwide
Run by
AstraZeneca
See details and how to joinNCT07529717
Phase 1Taking people
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Where
Seoul
Age
19 years and over
People
30
Run by
Cellbion Co., Ltd.
See details and how to joinNCT07244393
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Seoul
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Seoul
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Where
Gyeonggi-do, Seoul
Age
18 years and over
People
684 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07802704 · EU 2026-525558-13-00
Phase 3Taking people
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
Where
Gyeonggi-do, Seoul, Suwon
Age
19 years and over
People
114
Run by
FutureChem
See details and how to joinNCT07853209
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Seoul
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 1Taking people
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Where
Seoul
Age
18 years and over
People
83 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Seoul
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 2/3Taking people
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Where
Seoul
Age
18 years to 100 years
People
443 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Seoul
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Daegu, Gwangju, Seoul
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1/2Taking people
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Where
Seoul
Age
18 years and over
People
52 worldwide
Run by
AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00
Phase 1Taking people
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Where
Seoul
Age
18 years and over
People
479 worldwide
Run by
Amgen
See details and how to joinNCT04221542 · EU 2023-504361-23-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Daegu, Goyang-si, Incheon, Seoul
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
No phaseTaking people
Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer
Where
Goyang-si
Age
19 years and over
People
50
Run by
National Cancer Center, Korea
See details and how to joinNCT07699705
No phaseTaking people
Post Marketing Study on Pluvicto in Korea
Where
Busan, Gyeonggi-do, Jeollanam, Seongnam-si, Seoul, Suwon
Age
18 years to 100 years
People
278
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06514521
Phase 1Not yet taking people in South Korea
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
Where
Seoul
Age
19 years and over
People
18
Run by
Hyundai Bioscience Co., Ltd.
See details and how to joinNCT07683013
Phase 2Taking people
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Where
Seoul
Age
19 years and over
People
60
Run by
Inkeun Park
See details and how to joinNCT06893783
Phase 3Taking people
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
Where
Seoul
Age
20 years and over
People
270
Run by
Samsung Medical Center
See details and how to joinNCT07500701
No phaseTaking people
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Where
Seoul
Age
20 years and over
People
1,432
Run by
In Gab Jeong, MD
See details and how to joinNCT07398690